News

A clinical trial is underway to look for early signs of hereditary ATTR-CM in Black Americans with a specific genetic change.

In a recent webinar hosted by the Amyloidosis Research Consortium, Jan Griffin, MD discussed the expanding therapeutic landscape for ATTR-CM.

New research finds worsening symptoms significantly affect quality of life in people with ATTR-CM and cause caregivers strain.

The European Union has granted Orphan Drug Designation to the radioactive tracer florbetaben (18F) for the diagnosis of ATTR-CM.

Cardiac magnetic resonance imaging is valuable even in patients with amyloidosis without obvious heart disease.

There appear to be key differences between men and women regarding prevalence, prognosis, and survival in wild-type ATTR-CM.

Researchers developed a new dashboard to identify African American veterans at risk of cardiac amyloidosis, including hereditary ATTR-CM.

Nearly 1 in 3 older adults with heart issues or carpal tunnel may have undiagnosed ATTR-CM, a new study shows.

A recent study suggests that the gut microbiome might affect how hereditary transthyretin amyloid cardiomyopathy develops.

A new study building on the results of the HELIOS-B trial found further evidence of vutrisiran’s beneficial effects for people with ATTR-CM.